Literature DB >> 17985056

Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy.

M Maskew1, P MacPhail, C Menezes, D Rubel.   

Abstract

BACKGROUND: Patients who do not return for follow-up at clinics providing comprehensive HIV/AIDS care require special attention. This is particularly true where resources are limited and clinic loads are high. Themba Lethu Clinic at Helen Joseph Hospital in Johannesburg is a facility supported by PEPFAR funding through Right to Care (Grant CA-574-A-00-02-00018); more than 800 HIV/AIDS patients are seen there each week. Data on a sample of patients who failed to return for follow-up were analysed to identify the causes and to plan strategies to overcome the problem.
METHODS: A group of 182 patients who missed follow-up appointments at the clinic were identified. Their files were examined to identify possible contributing factors. The patients were then contacted telephonically and asked their reasons for non-attendance.
RESULTS: Results show that the leading cause of failure to follow up was financial (34% of patients). Patients cited transport costs and having to pay to open a file at each visit as the biggest monetary obstacles to obtaining treatment. Fifty-five per cent of patients lost to follow-up showed an improvement in CD4 count on treatment. Death accounted for 27% of the patients lost to follow-up and the mean ( +/- standard deviation (SD)) duration of treatment in this group was only 8 ( +/- 6) weeks. Of the patients in this group who had been seen at 4 months, 60% had failed to respond to treatment. The mean duration of ARV treatment before being lost to follow-up was 21 ( +/- 28) weeks. The mean CD4+ count was 92 ( +/- 74.5) cells/ microl and the mean number of visits was 3.33 ( +/- 2.17). Seventy-four per cent of the patients were on regimen 1A, and only 1 cited side-effects of medication as a reason for not returning.
CONCLUSIONS: This study highlighted financial difficulty as the major obstacle to obtaining treatment. There is evidence in support of providing ARV treatment free of charge to HIVpositive patients who qualify, as occurs in other provinces in South Africa. It is also suggested that providing ARV therapy at more local clinics in the community would make treatment more accessible. Provision of several months' supply of medicines per visit would help to reduce transport costs and minimise patient expenditure. These interventions may reduce the incidence of patients lost to follow-up in this community.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985056

Source DB:  PubMed          Journal:  S Afr Med J


  73 in total

1.  Monitoring of early warning indicators for HIV drug resistance in antiretroviral therapy clinics in Zimbabwe.

Authors:  J Dzangare; E Gonese; O Mugurungi; T Shamu; T Apollo; D E Bennett; K F Kelley; M R Jordan; C Chakanyuka; F Cham; R M Banda
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa.

Authors:  Elvin H Geng; David V Glidden; David R Bangsberg; Mwebesa Bosco Bwana; Nicholas Musinguzi; Denis Nash; John Z Metcalfe; Constantin T Yiannoutsos; Jeffrey N Martin; Maya L Petersen
Journal:  Am J Epidemiol       Date:  2012-02-03       Impact factor: 4.897

3.  Socioeconomic support reduces nonretention in a comprehensive, community-based antiretroviral therapy program in Uganda.

Authors:  Stella Talisuna-Alamo; Robert Colebunders; Joseph Ouma; Pamela Sunday; Kenneth Ekoru; Marie Laga; Glenn Wagner; Fred Wabwire-Mangen
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

4.  Long-term antiretroviral treatment outcomes in seven countries in the Caribbean.

Authors:  Serena P Koenig; Luis A Rodriguez; Courtenay Bartholomew; Alison Edwards; Tracie E Carmichael; Geoffrey Barrow; André Cabié; Robert Hunter; Giselle Vasquez-Mora; Avion Quava-Jones; Nicholas Adomakoh; J Peter Figueroa; Bernard Liautaud; Magaly Torres; Jean W Pape
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

5.  Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.

Authors:  Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne
Journal:  Int J Epidemiol       Date:  2012-03-20       Impact factor: 7.196

6.  Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007.

Authors:  Morna Cornell; Anna Grimsrud; Lara Fairall; Matthew P Fox; Gilles van Cutsem; Janet Giddy; Robin Wood; Hans Prozesky; Lerato Mohapi; Claire Graber; Matthias Egger; Andrew Boulle; Landon Myer
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

7.  The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa.

Authors:  Elena Losina; Ingrid V Bassett; Janet Giddy; Senica Chetty; Susan Regan; Rochelle P Walensky; Douglas Ross; Callie A Scott; Lauren M Uhler; Jeffrey N Katz; Helga Holst; Kenneth A Freedberg
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

8.  Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa.

Authors:  Martin W G Brinkhof; Ben D Spycher; Constantin Yiannoutsos; Ralf Weigel; Robin Wood; Eugène Messou; Andrew Boulle; Matthias Egger; Jonathan A C Sterne
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

9.  Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.

Authors:  Mhairi Maskew; Alana T Brennan; Daniel Westreich; Lynne McNamara; A Patrick MacPhail; Matthew P Fox
Journal:  J Womens Health (Larchmt)       Date:  2013-01-25       Impact factor: 2.681

10.  Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

Authors:  Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg
Journal:  PLoS Med       Date:  2009-10-27       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.